Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | ATF4 | P18848 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23110345 | 0.82 | RAB9A (0.58) | HRH4HTR3AMCHR1 | |
| SCHEMBL239841 | 0.81 | HRH3 (0.61) | HRH3HRH4HTR3APDE10AP2RX7 | |
| SCHEMBL23110348 | 0.79 | HRH4 (0.44) | HRH3HRH4HTR3AP2RX7MCHR1 | |
| SCHEMBL23110346 | 0.79 | HRH4 (0.46) | HRH4HTR3AP2RX7OPRK1 | |
| SCHEMBL27629095 | 0.76 | PDE10A (0.53) | HRH3HRH4HTR3APDE10AATF4 | |
| SCHEMBL24844621 | 0.75 | HRH3 (0.62) | HRH3HRH4HTR3APDE10AHTR3E | |
| SCHEMBL346050 | 0.75 | HRH3 (0.56) | HRH3HRH4HTR3APDE10AP2RX7 | |
| SCHEMBL5780233 | 0.75 | HTR3A (0.70) | HRH3HRH4HTR3APDE10AHTR3E | |
| SCHEMBL16695094 | 0.74 | HRH4 (0.74) | HRH3HRH4HTR3APDE10AHTR3E | |
| SCHEMBL1728851 | 0.74 | HRH3 (0.58) | HRH3HRH4HTR3APDE10AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315568-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021050913-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315568-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | HRH3 4272/4885HRH4 4644/4885HTR3A 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.